Boston Scientific Acquires Penumbra at $374 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2026
0mins
Should l Buy BSX?
Source: Benzinga
- Acquisition Deal: Boston Scientific has agreed to acquire Penumbra at $374 per share, valuing the transaction at approximately $14.5 billion, indicating strong interest in the medical device market and expected to enhance Boston Scientific's product portfolio and market share.
- Shareholder Options: Penumbra shareholders can choose between cash or Boston Scientific stock, with an overall proration of about 73% cash and 27% equity, which may attract more investor participation and enhance shareholder satisfaction.
- Strong Performance: Penumbra's preliminary fourth-quarter results exceeded expectations, with shares rising 12.1% to $351.25 on Thursday, reflecting market confidence in its future growth potential and likely boosting investor sentiment further.
- Market Reaction: The acquisition news significantly boosted Penumbra's stock price, demonstrating a positive market response to M&A activities in the healthcare sector, which may also trigger similar acquisition activities among other related companies, further energizing the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 71.200
Low
94.00
Averages
108.14
High
132.00
Current: 71.200
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Class Action Lawsuit Announcement
- Class Action Initiation: Boston Scientific faces a class action lawsuit for false statements made between July 23, 2025, and February 3, 2026, with investors having until May 4, 2026, to apply as lead plaintiffs, indicating significant legal risks for the company.
- Declining Financial Performance: The financial results announced on February 4, 2026, revealed a GAAP net income of $672 million for Q4 2025, an 18.7% increase year-over-year, but an EPS of $0.45 fell short of the expected range of $0.48 to $0.52, reflecting negative impacts from increased market competition.
- Market Share Erosion: Allegations in the lawsuit claim that Boston Scientific failed to disclose competitive pressures in the U.S. electrophysiology market, leading to a decline in market share and limiting growth potential, which could undermine investor confidence moving forward.
- Legal Affairs Impact: Robbins Geller Rudman & Dowd LLP, the leading law firm, has recovered $8.4 billion for investors over the past five years, showcasing its strength in securities fraud litigation, which may have long-term implications for Boston Scientific's stock price and reputation.
See More
Boston Scientific Securities Litigation Reminder for Investors
- Legal Action Initiated: Faruq & Faruq LLP is investigating potential claims against Boston Scientific, particularly for investors who purchased securities between July 23, 2025, and February 3, 2026, urging them to seek lead plaintiff status by the May 4, 2026 deadline to protect their legal rights.
- Disappointing Performance: Boston Scientific's February 4, 2026 earnings report revealed that U.S. EP sales fell short of expectations, resulting in a significant net income miss and a 17.6% drop in stock price to $75.50 per share, directly impacting investor confidence and market performance.
- Management Misrepresentation: The complaint alleges that Boston Scientific and its executives violated federal securities laws by failing to disclose the true state of the U.S. EP segment's growth, leading investors to misjudge the company's future prospects and affecting their investment decisions.
- Investor Rights Protection: Faruq & Faruq LLP encourages anyone with information regarding Boston Scientific's conduct, including whistleblowers and former employees, to come forward to provide legal support for affected investors, ensuring their rights are upheld.
See More
Multiple Companies Face Class Action Lawsuits
- Lakeland Industries Lawsuit: Lakeland Industries faces a class action lawsuit for the period from December 2023 to December 2025, alleging failure to disclose significant issues with its Pacific Helmets and Jolly businesses, including production delays and slow new product rollouts, which misled investors about the company's financial health.
- Franklin BSP Realty Lawsuit: Franklin BSP Realty Trust is under a class action lawsuit for the period from November 2024 to February 2026, accused of overstating its ability to maintain a $0.355 dividend, misleading investors about the company's future prospects.
- Apollo Global Lawsuit: Apollo Global Management is facing a class action lawsuit for the period from May 2021 to February 2026, alleging undisclosed communications between executives and Jeffrey Epstein, which harmed the company's reputation and rendered positive statements about its operations misleading.
- Boston Scientific Lawsuit: Boston Scientific is involved in a class action lawsuit for the period from July 2025 to February 2026, accused of being overly optimistic about the growth of its U.S. electrophysiology segment while failing to disclose increasing market competition, misleading investors regarding the company's growth potential.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Boston Scientific Corporation is facing a class action lawsuit for alleged violations of federal securities laws, with plaintiffs being investors who purchased its securities between July 23, 2025, and February 3, 2026, seeking damages for losses incurred.
- False Statements Allegations: The complaint alleges that throughout the relevant period, the company made materially false and misleading statements, failing to disclose that the growth rate of its U.S. electrophysiology segment was unsustainable, leading to investor misconceptions about the company's prospects.
- Market Impact: Plaintiffs claim that despite experiencing declining procedure volumes, increasing competitive pressures, and regulatory hurdles, Boston Scientific continued to express confidence in its electrophysiology division's growth, resulting in significant investor losses.
- Legal Implications: Investors have until May 4, 2026, to apply to be lead plaintiffs, and Boston Scientific investors may recover costs on a contingency basis, indicating potential negative repercussions for the company's future stock price and reputation.
See More
Boston Scientific Shareholder Notice Issued
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Boston Scientific Corporation (NYSE:BSX), encouraging those who purchased shares during the class period from July 23, 2025, to February 3, 2026, to contact the firm regarding potential lead plaintiff appointment for class action participation.
- Allegations of Misrepresentation: The complaint alleges that Boston Scientific's management made overly positive statements while concealing the unsustainable growth rate of its U.S. EP segment, which misled investors and analysts, ultimately resulting in a significant net income miss.
- Dramatic Stock Decline: Following the disappointing fourth-quarter results and guidance issued on February 4, 2026, Boston Scientific's stock plummeted from $91.62 per share to $75.50, marking a 17.6% drop in just one day, indicating severe market disappointment regarding the company's outlook.
- Steps for Legal Participation: Shareholders must register by May 4, 2026, to participate in the class action lawsuit, and upon registration, they will receive updates on the case's progress, ensuring they remain informed and can pursue potential recovery of losses.
See More
Boston Scientific Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Participants are not required to pay any upfront fees or costs, as the law firm will handle the case through a contingency fee arrangement, ensuring investors can seek compensation without financial burden.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, leading to investor losses when the company missed net income expectations, highlighting management's misjudgment of the electrophysiology segment's growth rate.
- Law Firm Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its success and resource advantages in handling such cases.
See More
Boston Scientific Class Action Lawsuit Announcement
- Class Action Initiation: Boston Scientific faces a class action lawsuit for false statements made between July 23, 2025, and February 3, 2026, with investors having until May 4, 2026, to apply as lead plaintiffs, indicating significant legal risks for the company.
- Declining Financial Performance: The financial results announced on February 4, 2026, revealed a GAAP net income of $672 million for Q4 2025, an 18.7% increase year-over-year, but an EPS of $0.45 fell short of the expected range of $0.48 to $0.52, reflecting negative impacts from increased market competition.
- Market Share Erosion: Allegations in the lawsuit claim that Boston Scientific failed to disclose competitive pressures in the U.S. electrophysiology market, leading to a decline in market share and limiting growth potential, which could undermine investor confidence moving forward.
- Legal Affairs Impact: Robbins Geller Rudman & Dowd LLP, the leading law firm, has recovered $8.4 billion for investors over the past five years, showcasing its strength in securities fraud litigation, which may have long-term implications for Boston Scientific's stock price and reputation.
See More
Boston Scientific Securities Litigation Reminder for Investors
- Legal Action Initiated: Faruq & Faruq LLP is investigating potential claims against Boston Scientific, particularly for investors who purchased securities between July 23, 2025, and February 3, 2026, urging them to seek lead plaintiff status by the May 4, 2026 deadline to protect their legal rights.
- Disappointing Performance: Boston Scientific's February 4, 2026 earnings report revealed that U.S. EP sales fell short of expectations, resulting in a significant net income miss and a 17.6% drop in stock price to $75.50 per share, directly impacting investor confidence and market performance.
- Management Misrepresentation: The complaint alleges that Boston Scientific and its executives violated federal securities laws by failing to disclose the true state of the U.S. EP segment's growth, leading investors to misjudge the company's future prospects and affecting their investment decisions.
- Investor Rights Protection: Faruq & Faruq LLP encourages anyone with information regarding Boston Scientific's conduct, including whistleblowers and former employees, to come forward to provide legal support for affected investors, ensuring their rights are upheld.
See More
Multiple Companies Face Class Action Lawsuits
- Lakeland Industries Lawsuit: Lakeland Industries faces a class action lawsuit for the period from December 2023 to December 2025, alleging failure to disclose significant issues with its Pacific Helmets and Jolly businesses, including production delays and slow new product rollouts, which misled investors about the company's financial health.
- Franklin BSP Realty Lawsuit: Franklin BSP Realty Trust is under a class action lawsuit for the period from November 2024 to February 2026, accused of overstating its ability to maintain a $0.355 dividend, misleading investors about the company's future prospects.
- Apollo Global Lawsuit: Apollo Global Management is facing a class action lawsuit for the period from May 2021 to February 2026, alleging undisclosed communications between executives and Jeffrey Epstein, which harmed the company's reputation and rendered positive statements about its operations misleading.
- Boston Scientific Lawsuit: Boston Scientific is involved in a class action lawsuit for the period from July 2025 to February 2026, accused of being overly optimistic about the growth of its U.S. electrophysiology segment while failing to disclose increasing market competition, misleading investors regarding the company's growth potential.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Boston Scientific Corporation is facing a class action lawsuit for alleged violations of federal securities laws, with plaintiffs being investors who purchased its securities between July 23, 2025, and February 3, 2026, seeking damages for losses incurred.
- False Statements Allegations: The complaint alleges that throughout the relevant period, the company made materially false and misleading statements, failing to disclose that the growth rate of its U.S. electrophysiology segment was unsustainable, leading to investor misconceptions about the company's prospects.
- Market Impact: Plaintiffs claim that despite experiencing declining procedure volumes, increasing competitive pressures, and regulatory hurdles, Boston Scientific continued to express confidence in its electrophysiology division's growth, resulting in significant investor losses.
- Legal Implications: Investors have until May 4, 2026, to apply to be lead plaintiffs, and Boston Scientific investors may recover costs on a contingency basis, indicating potential negative repercussions for the company's future stock price and reputation.
See More
Boston Scientific Shareholder Notice Issued
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Boston Scientific Corporation (NYSE:BSX), encouraging those who purchased shares during the class period from July 23, 2025, to February 3, 2026, to contact the firm regarding potential lead plaintiff appointment for class action participation.
- Allegations of Misrepresentation: The complaint alleges that Boston Scientific's management made overly positive statements while concealing the unsustainable growth rate of its U.S. EP segment, which misled investors and analysts, ultimately resulting in a significant net income miss.
- Dramatic Stock Decline: Following the disappointing fourth-quarter results and guidance issued on February 4, 2026, Boston Scientific's stock plummeted from $91.62 per share to $75.50, marking a 17.6% drop in just one day, indicating severe market disappointment regarding the company's outlook.
- Steps for Legal Participation: Shareholders must register by May 4, 2026, to participate in the class action lawsuit, and upon registration, they will receive updates on the case's progress, ensuring they remain informed and can pursue potential recovery of losses.
See More
Boston Scientific Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Participants are not required to pay any upfront fees or costs, as the law firm will handle the case through a contingency fee arrangement, ensuring investors can seek compensation without financial burden.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, leading to investor losses when the company missed net income expectations, highlighting management's misjudgment of the electrophysiology segment's growth rate.
- Law Firm Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its success and resource advantages in handling such cases.
See More
